Daily Endocrinology Research Analysis
Analyzed 91 papers and selected 3 impactful papers.
Summary
Analyzed 91 papers and selected 3 impactful articles.
Selected Articles
1. Mitochondrial control of glycerolipid synthesis by a PEP shuttle.
This mechanistic study identifies SLC25A35 as a mitochondrial phosphoenolpyruvate (PEP) exporter that drives glyceroneogenesis and glycerolipid synthesis in lipogenic cells. Structural/reconstitution assays confirmed PEP transport, and liver-specific inhibition in obese mice alleviated steatosis and improved systemic glucose homeostasis, highlighting a druggable mitochondrial node in NAFLD and type 2 diabetes.
Impact: Reveals a previously unknown mitochondrial PEP shuttle controlling lipid synthesis and demonstrates therapeutic modulation in vivo, offering a compelling target for metabolic liver disease.
Clinical Implications: Targeting SLC25A35 or the mitochondrial PEP shuttle could reduce hepatic triglyceride synthesis and improve glycemic control in NAFLD and type 2 diabetes; it supports development of liver-directed inhibitors or nutrient strategies (e.g., modulating the pyruvate-to-PEP bypass).
Key Findings
- SLC25A35 mediates pH gradient–dependent mitochondrial PEP efflux, fueling glyceroneogenesis.
- Loss of SLC25A35 in adipocytes reduces conversion of mitochondrial PEP to glycerol-3-phosphate and diminishes glycerolipid synthesis.
- Hepatic inhibition of SLC25A35 in obese mice alleviates steatosis and improves systemic glucose homeostasis.
Methodological Strengths
- Multimodal validation including reconstitution and structural analyses to prove PEP transport by SLC25A35.
- In vivo functional relevance demonstrated by liver-targeted inhibition improving steatosis and glycemia in obese mice.
Limitations
- Preclinical models; human translational efficacy and safety of SLC25A35 inhibition remain untested.
- Specificity and potential compensatory pathways for mitochondrial PEP transport in diverse tissues require clarification.
Future Directions: Define pharmacology and safety of selective SLC25A35 inhibitors; validate pathway activity and biomarkers in human NAFLD/T2D; assess tissue specificity and long-term metabolic/cardiac effects.
Mitochondria provide a variety of metabolites, in addition to ATP, to meet cell-specific needs. One such metabolite is phosphoenolpyruvate (PEP), which contains a higher-energy phosphate bond than ATP and has diverse biological functions. However, how mitochondria-generated PEP is delivered to the cytosol and fulfills cell-specific requirements remains elusive. Here, we show that SLC25A35 regulates mitochondrial PEP efflux and glyceroneogenesis in lipogenic cells that utilize the pyruvate-to-PEP bypass. Reconstitution and s
2. Hypothalamic clock governs circadian pain.
Using a neuropathic pain model, the authors identify a rhythmic circuit from the suprachiasmatic nucleus (SCN) to the descending analgesia system that drives daily oscillations in nociceptive thresholds. SCN vasoactive intestinal peptide (VIP) neuron activity varies with the light-dark cycle, mechanistically linking the hypothalamic clock to circadian pain.
Impact: Defines a master-clock-to-analgesia circuit for circadian pain, providing a mechanistic basis for chronotherapeutic strategies in pain management.
Clinical Implications: Chronotherapy for chronic pain could be optimized by aligning analgesic dosing and neuromodulation with SCN-driven rhythms; timing of interventions may enhance efficacy and reduce side effects.
Key Findings
- Nociceptive thresholds exhibit daily oscillations in a mouse neuropathic pain model.
- A rhythmic SCN-to-descending analgesia circuit drives circadian variation in pain sensitivity.
- SCN VIP neuron activity is elevated during the resting (daytime) phase, linking hypothalamic clock output to pain modulation.
Methodological Strengths
- Systems-level circuit dissection linking hypothalamic clock neurons to pain pathways in vivo.
- Use of a defined neuropathic pain model enabling causal inference about rhythmic control.
Limitations
- Rodent model limits direct generalization to human chronic pain.
- Abstracted data provide limited detail on specific circuit nodes and techniques; translational biomarkers are not yet defined.
Future Directions: Map human homologous circuits and identify time-of-day biomarkers of pain; test time-locked analgesic regimens and neuromodulation in clinical trials.
Chronic pain exhibits circadian rhythms in humans, but the mechanisms underlying such rhythmicity remain unclear. Here, we found daily oscillations in the nociceptive thresholds in a mouse model of neuropathic pain, driven by a rhythmic circuit from the master clock in the hypothalamus to the descending analgesia system. In the daytime (resting phase), higher vasoactive intestinal peptide (VIP) neuronal activity in suprachiasmatic nucleus (SCN
3. Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population-Based Comparison.
In a nationwide cohort of 1.32 million adults, dementia risk was elevated in all diabetes groups, with the highest risk in type 1 diabetes and insulin-treated type 2 diabetes. Findings implicate insulin-requiring diabetes as a high-risk cognitive phenotype and support proactive cognitive screening and strategies to reduce glycemic variability.
Impact: Provides precise, treatment-stratified dementia risk estimates across diabetes phenotypes at population scale, informing screening and prevention policies.
Clinical Implications: Prioritize cognitive screening in type 1 diabetes and insulin-treated type 2 diabetes; optimize glycemic control and reduce variability (e.g., CGM-guided care) to potentially mitigate dementia risk.
Key Findings
- All-cause dementia incidence per 1000 person-years: 4.3 (non-diabetic), 12.7 (T2DM on OHAs), 17.9 (T2DM on insulin), 21.1 (T1DM).
- Adjusted HRs vs. non-diabetic for all-cause dementia: 1.29 (T2DM with OHAs), 2.14 (T2DM with insulin), 2.35 (T1DM); similar trends for AD and VaD.
- Dementia risk was highest and comparable between T1DM and insulin-treated T2DM, identifying insulin-requiring diabetes as a high-risk phenotype.
Methodological Strengths
- Very large, nationwide population-based cohort with comprehensive adjustment for demographic, lifestyle, and clinical covariates.
- Clear phenotype stratification (T1DM vs. T2DM with/without insulin) and consistent results across dementia subtypes.
Limitations
- Observational design prone to residual confounding and misclassification (claims-based dementia ascertainment).
- Glycemic variability, diabetes duration, and hypoglycemia burden were not directly measured.
Future Directions: Prospective studies integrating CGM metrics, hypoglycemia exposure, and neuroimaging/biomarkers to test mechanisms and time-targeted prevention in insulin-requiring diabetes.
AIMS: Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all-cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes. METHODS: This population-based retrospective cohort study analysed data from the Korean National Health Insurance Service (2013-2024). A total of 1 322 651 adults aged ≥ 40 years without prior dementia were included. Participants were classified as non-diabetic, type 2 diabetes (T2DM) with oral hypoglycemic agents (OHAs), T2DM with insulin, or type 1 diabetes (T1DM). Incident dementia was identified using ICD-10 codes and anti-dementia prescriptions. Multivariable Cox proportional hazards models adjusted for demographic, lifestyle and clinical factors estimated adjusted hazard ratios (aHRs) for dementia. RESULTS: Dementia incidence rates per 1000 person-years were 4.3 (non-diabetic), 12.7 (T2DM with OHA), 17.9 (T2DM with insulin) and 21.1 (T1DM). Compared with non-diabetic participants, aHRs for all-cause dementia were 1.29 (95% CI 1.26-1.32) for T2DM with OHA, 2.14 (2.00-2.28) for T2DM with insulin and 2.35 (2.12-2.59) for T1DM. Similar trends were observed for AD and VaD. Dementia risk was highest in individuals with T1DM and insulin-treated T2DM, with no significant difference between these groups. CONCLUSIONS: Diabetes was associated with a higher risk of dementia, particularly among individuals with T1DM and insulin-treated T2DM, suggesting that insulin-requiring diabetes represents a high-risk phenotype for cognitive decline. Proactive cognitive screening and optimised glycemic management, including strategies to reduce glycemic variability such as continuous glucose monitoring, may help mitigate dementia risk in these vulnerable populations.